Enhancement of bone healing using non-glycosylated rhBMP-2 released from a fibrin matrix in dogs and cats

Objectives: To test a non‐glycosylated recombinant human bone morphogenetic protein‐2 (ngly‐rhBMP‐2)/fibrin composite, which has been shown experimentally to enhance healing of bone defects in rodents, in a clinical case series of dogs and cats undergoing treatment for fracture non‐unions and arthro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of small animal practice 2005, Vol.46 (1), p.17-21
Main Authors: Schmoekel, H.G, Weber, F.E, Hurter, K, Schense, J.C, Seiler, G, Rytz, U, Spreng, D, Schawalder, P, Hubbell, J
Format: Article
Language:English
Subjects:
Animals
autografting
bone fractures
Bone Morphogenetic Protein 2
Bone Morphogenetic Proteins - therapeutic use
Bone Substitutes
cats
Cats - injuries
dogs
Dogs - injuries
drug delivery systems
drug therapy
Female
Fibrin
Fracture Fixation - methods
Fracture Fixation - veterinary
Fracture Healing - drug effects
humans
Male
product testing
Prospective Studies
recombinant proteins
rodents
tissue repair
Transforming Growth Factor beta - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To test a non‐glycosylated recombinant human bone morphogenetic protein‐2 (ngly‐rhBMP‐2)/fibrin composite, which has been shown experimentally to enhance healing of bone defects in rodents, in a clinical case series of dogs and cats undergoing treatment for fracture non‐unions and arthrodesis. Methods: A ngly‐rhBMP‐2/fibrin composite was applied in 41 sites in 38 dogs and cats for which a cancellous bone autograft was indicated, replacing the graft. Results: Bridging of the bone defect with functional bone healing was achieved in 90 per cent of the arthrodesis and fracture nonunions treated in this manner. Clinical Significance: This prospective clinical study demonstrates the beneficial effects of ngly‐rhBMP‐2 in a specially designed fibrin matrix on the treatment of bone defects, and validates the use of this composite as an alternative to bone autografts in dogs and cats.
ISSN:0022-4510
1748-5827
DOI:10.1111/j.1748-5827.2005.tb00269.x